We provide you with 20 years of free, institutional-grade data for RUBY stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RUBY. Explore the full financial landscape of RUBY stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about RUBY stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Rubius Therapeutics, Inc(NASDAQ:RUBY) 
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematologic...
Website: http://www.rubiustx.com
Founded: 2014
Full Time Employees: 231 (May 2021)
CEO: Pablo J Cagnoni
Sector: Healthcare
Industry: Biotechnology